Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Klimawandel und Gesundheit Neues aus dem Markt COVID-19 Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende
Erweiterte Suche
Anmelden
nach oben
Current Oncology Reports
Erschienen in: Current Oncology Reports 8/2018

01.08.2018 | Gastrointestinal Cancers (J Meyer, Section Editor)

Peritoneal Metastases from Gastrointestinal Cancer

verfasst von: Paul H. Sugarbaker

Erschienen in: Current Oncology Reports | Ausgabe 8/2018

Einloggen, um Zugang zu erhalten

Abstract

Purpose of Review

Peritoneal metastases may occur from a majority of cancers that occur within the abdomen or pelvis. When cancer spread to the peritoneal surfaces is documented, a decision regarding palliation vs. an aggressive approach using cytoreductive surgery (CRS) and perioperative intraperitoneal chemotherapy must be made. The perioperative chemotherapy may be hyperthermic intraperitoneal chemotherapy (HIPEC) administered in the operating room or early postoperative intraperitoneal chemotherapy (EPIC) administered in the first 4 or 5 postoperative days.

Recent Findings

This decision is dependent on a well-defined group of prognostic indicators. In addition to treatment, the clinical and pathologic features of a primary cancer can be used to select perioperative treatments that may prevent cancer cells within the abdomen and pelvis from progressing to established peritoneal metastases. In some clinical situations with appendiceal and colorectal cancers, the clinical or histopathologic features may indicate that second-look surgery plus perioperative chemotherapy should occur.

Summary

Peritoneal metastases should always be considered for treatment or prevention.
Literatur
1.
Sugarbaker PH. New standard of care for appendiceal epithelial malignancies and pseudomyxoma peritonei syndrome. Lancet Oncol. 2006;7(1):69–76.CrossRefPubMed
2.
•• Sugarbaker PH, Turaga KK, Alexander HR Jr, Deraco M, Hesdorffer M. Management of malignant peritoneal mesothelioma using cytoreductive surgery and perioperative chemotherapy. J Oncol Pract. 2016;12(10):928–35. New standard of care for malignant peritoneal mesothelioma. CrossRefPubMed
3.
4.
•• Tewari D, Java JJ, Salani R, et al. Long-term survival advantage and prognostic factors associated with intraperitoneal chemotherapy treatment in advanced ovarian cancer: a gynecologic oncology group study. J Clin Oncol. 2015;33:1460–6. Importance of normothermic intraperitoneal chemotherapy long-term. CrossRefPubMedPubMedCentral
5.
Sugarbaker PH, Kwong ML. Regional chemotherapy: possibilities for prevention and treatment of peritoneal metastases from gastric cancer. (In) Management of Gastric Cancer. SMGroup at www.​smgbooks.​com.
6.
• Goere D, Passot G, Gelli M, Sugarbaker PH, Glehen O. Complete cytoreductive surgery plus HIPEC for peritoneal metastases from unusual cancer sites of origin: results from a worldwide analysis of the Peritoneal Surface Oncology Group International (PSOGI). Int J Hyperthermia. 2017;33:528–33. Update of treatment of peritoneal metastases from rare cancers. CrossRef
7.
Chu DZ, Lang NP, Thompson C, Osteen PK, Westbrook KC. Peritoneal carcinomatosis in nongynecologic malignancy: a prospective study of prognostic factors. Cancer. 1989;63:364–7.CrossRefPubMed
8.
Sadeghi B, Arvieux C, Glehen O, Beaujard AC, Rivoire M, Baulieux J, et al. Peritoneal carcinomatosis from non-gynecologic malignancies. Results of the EVOCAPE 1 multicentric prospective study. Cancer. 2000;88:358–63.CrossRefPubMed
9.
Jayne DG, Fook S, Loi C, Seow-Choen F. Peritoneal carcinomatosis from colorectal cancer. Br J Surg. 2002;89:1545–50.CrossRefPubMed
10.
Popovich RP, Moncrief JW, Nolph KD, Ghods AJ, Twardowski ZJ, Pyle WK. Continuous ambulatory peritoneal dialysis. Ann Intern Med. 1978;88:449–56.CrossRefPubMed
11.
Karnofsky DA, Abelmann WH, Craver LF, et al. The use of the nitrogen mustards in the palliative treatment of carcinoma. Cancer. 1948;40:634–56.CrossRef
12.
Torres IJ, Litterst CL, Guarino AM. Transport of model compounds across the peritoneal membrane in the rat. Pharmacology. 1978;17:330–40.CrossRefPubMed
13.
• Dedrick RL, Myers CE, Bungay PM, de Vita V Jr. Pharmacokinetic rationale for peritoneal drug administration in the treatment of ovarian cancer. Cancer Treat Rep. 1978;62, 1:–11. Establishes the pharmacologic rationale for intraperitoneal chemotherapy.
14.
Speyer JL, Collins JM, Dedrick RL, Brennan MF, Buckpitt AR, Londer H, et al. Phase 1 and pharmacologic studies of 5-fluorouracil administered intraperitoneally. Cancer Res. 1980;40:567–72.PubMed
15.
Speyer JL, Sugarbaker PH, Collins JM, Dedrick RL, Klecker RW Jr, Myers CE. Portal levels and hepatic clearance of 5-fluorouracil after intraperitoneal administration in humans. Cancer Res. 1981;41:1916–22.PubMed
16.
Jones RB, Myers CE, Guarino AM, Dedrick RL, Hubbard SM, DeVita V. High volume intraperitoneal chemotherapy (“belly bath”) for ovarian cancer. Cancer Chemother Pharmacol. 1978;1:161–6.CrossRefPubMed
17.
Ozols RF, Locker GY, Doroshow JH, Grotzinger KR, Myers CE, Young RC. Pharmacokinetics of adriamycin and tissue penetration in murine ovarian cancer. Cancer Res. 1979;39:3209–14.PubMed
18.
McVie JG, Dikhoff T, Van der Heide J, et al. Tissue concentration of platinum after intraperitoneal cisplatinum in patients (PTS). Proc Am Association Cancer Res. 1985;26:162.
19.
•• Sugarbaker PH, van der Speeten K. Surgical technology and pharmacology of hyperthermic perioperative chemotherapy. J Gastrointest Oncol 2016;7(1):29–44. Defines surgeon’s role in management of peritoneal metastases.
20.
Van der Speeten K, Stuart OA, Chang D, Mahteme H, Sugarbaker PH. Changes induced by surgical and clinical factors in the pharmacology of intraperitoneal mitomycin C in 145 patients with peritoneal carcinomatosis. Cancer Chemother Pharmacol. 2011;68:147–56.CrossRefPubMed
21.
Shiu MH, Fortner JG. Intraperitoneal hyperthermic treatment of implanted peritoneal cancer in rats. Cancer Res. 1980;40:4081–4.PubMed
22.
Meyer JL, Kapp DS, Fessenden P, Hahn GH. Hyperthermic oncology: current biology, physics and clinical results. Pharmac Ther. 1989;42:251–88.CrossRef
23.
• Spratt JS, Adcock RA, Muskovin M, Sherrill W, McKeown J. Clinical delivery system for intraperitoneal hyperthermic chemotherapy. Cancer Res 1980;40:256–60. The first HIPEC.
24.
Koga S, Hamazoe R, Maeta M, Shimizu N, Kanayama H, Osaki Y. Treatment of implanted peritoneal cancer in rats by continuous hyperthermic peritoneal perfusion in combination with an anticancer drug. Cancer Res. 1980;44:1840–2.
25.
Koga S, Hamazoe R, Maeta M, Shimizu N, Murakami A, et al. Prophylactic therapy for peritoneal recurrence of gastric cancer by continuous hyperthermic peritoneal perfusion with mitomycin C. 1988;61:232–237.
26.
Fujimura T, Yonemura Y, Muraoka K, Takamura H, Hirono Y, Sahara H, et al. Continuous hyperthermic peritoneal perfusion for the prevention of peritoneal recurrence of gastric cancer: randomized controlled study. World J Surg. 1994;18:150–5.CrossRefPubMed
27.
Fujimoto S, Takahashi M, Mutou T, Kobayashi K, Toyosawa T. Successful intraperitoneal hyperthermic chemoperfusion for the prevention of postoperative peritoneal recurrence in patients with advanced gastric carcinoma. Cancer. 1998;85:529–34.CrossRef
28.
Yan TD, Black D, Sugarbaker PH, Zhu J, Yonemura Y, Petrou G, et al. A systematic review and meta-analysis of the randomized controlled trials on adjuvant intraperitoneal chemotherapy for resectable gastric cancer. Ann Surg Oncol. 2007;14(10):2702–13.CrossRefPubMed
29.
Feingold PL, Kwong MLM, Sabesan A, Sorber R, Rudloff U. Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for gastric cancer and other less common disease histologies: is it time? J Gastrointest Oncol. 2016;7:87–98.PubMedPubMedCentral
30.
Yonemura Y, de Aretxabala X, Fujimura T, Fushida S, Katayama K, Bandou E, et al. Intraoperative chemohyperthermic peritoneal perfusion as an adjuvant to gastric cancer: final results of a randomized controlled study. Hepatogastroenterology. 2001;48:1776–82.PubMed
31.
ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). 2013 June 13. Identifier NCT01882933, D2 Resection and HIPEC (Hyperthermic Intraperitoneal Chemoperfusion) in Locally Advanced Gastric Carcinoma (GASTRICHIP); [cited 2017 April 22]; Available from: https://​clinicaltrials.​gov/​ct2/​show/​NCT01882933.
32.
Quirke P, Sebag-Montefiore D, Steele R, et al. Local recurrence after rectal cancer resection is strongly related to the plane of the surgical dissection and is further reduced by pre-operative short course radiotherapy. Preliminary results of the Medical Research Council (MRC) CR07 trial. J Clin Oncol. 2006;24:article 3512.CrossRef
33.
Heald RJ, Ryall RDH. Recurrence and survival after total mesorectal excision for rectal cancer. Lancet. 1986;1(8496):1479–82.CrossRefPubMed
34.
West NP, Hohenberger W, Weber K, Perrakis A, Finan PJ, Quirke P. Complete mesocolic excision with central vascular ligation produces an oncologically superior specimen compared with standard surgery for carcinoma of the colon. J Clin Oncol. 2010;28(2):272–8.CrossRefPubMed
35.
Sugarbaker PH. Colorectal cancer metastases, a surgical perspective. (In) Masters G (Ed). Surg Oncol Clin N Am. 2013;22(2):289–98.CrossRefPubMed
36.
•• Honore C, Gelli M, Francoul J, et al. Ninety percent of the adverse outcomes in 10% of patients: can we identify the populations at high risk of developing peritoneal metastases after curative surgery for colorectal cancer? Int J Hyperth 2017;33(5):505–10. Defines parameters for preventive treatments.
37.
Honore C, Goere D, Souadka A, Dumont F, Elias D. Definition of patient presenting a high risk of developing peritoneal carcinomatosis after curative surgery for colorectal cancer: a systematic review. Ann Surg Oncol. 2013;20:183–92.CrossRefPubMed
38.
Cunliffe WJ, Sugarbaker PH. Gastrointestinal malignancy: rationale for adjuvant therapy using early postoperative intraperitoneal chemotherapy (EPIC). Br J Surg 1989;76:1082–1090.
39.
Sugarbaker PH, Graves T, DeBruijn EA, Cunliffe WJ, Mullins RE, Hull WE, et al. Early postoperative intraperitoneal chemotherapy as an adjuvant therapy to surgery for peritoneal carcinomatosis from gastrointestinal cancer: pharmacologic studies. Cancer Res. 1990;50:5790–4.PubMed
40.
Sugarbaker PH. Successful management of microscopic residual disease in large bowel cancer. Cancer Chemother Pharmacol. 1999;43(Suppl):S15–25.CrossRefPubMed
41.
Jacquet P, Averbach A, Stephens AD, Stuart OA, Chang D, Sugarbaker PH. Heated intraoperative intraperitoneal mitomycin C and early postoperative intraperitoneal 5-fluorouracil: pharmacokinetic studies. Oncology. 1998;55:130–8.CrossRefPubMed
42.
Pestieau SR, Sugarbaker PH. Treatment of primary colon cancer with peritoneal carcinomatosis: a comparison of concomitant versus delayed management. Dis Colon Rectum. 2000;43:1341–8.CrossRefPubMed
43.
Tentes AA. Preliminary results with the use of hyperthermic intraoperative intraperitoneal chemotherapy or systemic chemotherapy in high-risk colorectal cancer patients. (submitted for publication).
44.
Noura S, Ohue M, Shingai T, Kano S, Ohigashi H, Yano M, et al. Effects of intraperitoneal chemotherapy with mitomycin C on the prevention of peritoneal recurrence in colorectal cancer patients with positive peritoneal lavage cytology findings. Ann Surg Oncol. 2011;18:396–404.CrossRefPubMed
45.
Braam HJ, Boerma D, Wiezer MJ, van Ramshorst. Hyperthermic intraperitoneal chemotherapy during primary tumour resection limits extent of bowel resection compared to two-stage treatment. Eur J Surg Oncol 2013;39:988–993.
46.
Sammartino P, Sibio S, Accarpio F, Di Giorgio A. Long-term results after proactive management for locoregional control in patients with colonic cancer at high risk of peritoneal metastases. Int J Color Dis. 2014;29:1081–9.CrossRef
47.
Yu W, Whang I, Chung HY, Averbach A, Sugarbaker PH. Indications for early postoperative intraperitoneal chemotherapy of advanced gastric cancer: results of a prospective randomized trial. World J Surg. 2001;25:985–90.CrossRefPubMed
48.
Glehen O, Kwiatkowski F, Sugarbaker PH, Elias D, Levine EA, de Simone M, et al. Cytoreductive surgery combined with perioperative intraperitoneal chemotherapy for management of peritoneal carcinomatosis from colorectal cancer: a multi-institutional study. J Clin Oncol. 2004;22(16):3284–92.CrossRefPubMed
49.
Sugarbaker PH, van der Speeten K, Stuart OA, Chang D, Mahteme H. Patient- and treatment-related variables, adverse events and their statistical relationship for treatment of peritoneal metastases. (In) Sugarbaker PH (Ed). Cytoreductive Surgery & Perioperative Chemotherapy for Peritoneal Surface Malignancy. Textbook and Video Atlas. Cine-Med Publishing: Woodbury, CT, 2012, pp. 183–206.
50.
51.
Sugarbaker PH, Sammartino P, Tentes AA. Proactive management of peritoneal metastases from colorectal cancer: the next logical step toward optimal locoregional control. Colorect Cancer. 2012;1(2):115–23.CrossRef
52.
Sammartino P, Tentes AA, Sugarbaker PH. Eradication of minimal residual disease in the perioperative period in primary colorectal cancer. Colorectal Cancer. 2015;4:157–66.CrossRef
53.
Sammartino P, Societa Italiana di Chirurgia Oncologica (SICO). PROMENADE trial (PROactive Management of ENdoperitoneal spreAD in colonic cancer). [cited 2017 September 19].
54.
Arjona Sanchez A. Prophylactic HIPEC for cT4 colon cancer (personal communication).
55.
Griffen WO, Humphrey L, Sosin H. The prognosis and management of recurrent abdominal malignancies. Curr Probl Surg 1969;Apr:3–41., 6, 1, 43
56.
Minton JP, Hoehn JL, Gerber DM, Horsley JS, Connolly DP, Salwan F, et al. Results of a 400-patient carcinoembryonic antigen second-look colorectal cancer study. Cancer. 1985;55:1284–90.CrossRefPubMed
57.
58.
• Elias D, Goere D, Di Pietrantonio, et al. Results of systematic second-look surgery in patients at high risk of developing colorectal peritoneal carcinomatosis. Ann Surg 2008;247;3:445–450. Established parameters for second-look surgery.
59.
Delhorme JB, Triki E, Romain B, Meyer N, Rohr S, Brigand C. Routine second-look after surgical treatment of colonic peritoneal carcinomatosis. J Visc Surg. 2015;152(3):149–54.CrossRefPubMed
60.
61.
• Sugarbaker PH. Peritonectomy procedures. Ann Surg. 1995;221:29–42. Procedures that make HIPEC possible for patients with established peritoneal metastases. CrossRefPubMedPubMedCentral
62.
Los G, Mutsaers PH, Lenglet WJ, Baldew GS, McVie JG. Platinum distribution in intraperitoneal tumors after intraperitoneal cisplatin treatment. Cancer Chemother Pharmacol. 1990;25:389–94.CrossRefPubMed
63.
Sugarbaker PH, Jablonski KA. Prognostic features of 51 colorectal and 130 appendiceal cancer patients with peritoneal carcinomatosis treated by cytoreductive surgery and intraperitoneal chemotherapy. Ann Surg. 1995;221(2):124–32.CrossRefPubMedPubMedCentral
64.
Sethna KS, Sugarbaker PH. New prospects for the control of peritoneal surface dissemination of gastric cancer using perioperative intraperitoneal chemotherapy. Cancer Therapy. 2004;2:79–84.
65.
Sugarbaker PH. Strategies for the prevention and treatment of peritoneal carcinomatosis from gastrointestinal cancer. Cancer Investig. 2005;23:155–72.CrossRef
66.
• Jacquet P, Sugarbaker PH. Current methodologies for clinical assessment of patients with peritoneal carcinomatosis. J Exp Clin Cancer Res. 1996;15(1):49–58. Established prognostic indicators for peritoneal metastases.
67.
da Silva RG, Sugarbaker PH. Analysis of prognostic factors in seventy patients having a complete cytoreduction plus perioperative intraperitoneal chemotherapy for carcinomatosis from colorectal cancer. J Am Coll Surg. 2006;203(6):878–86.CrossRefPubMed
68.
Glehen O, Gilly FN, Arvieux C, et al. Peritoneal carcinomatosis from gastric cancer: a multi-institutional study of 159 patients treated by cytoreductive surgery combined with perioperative intraperitoneal chemotherapy. Ann Surg Oncol. 2010;17(9):2370–7.CrossRefPubMed
69.
Lampe B, Kroll N, Piso P, Forner DM, Mallman P. Prognostic significance of Sugarbaker’s peritoneal cancer index for the operability of ovarian carcinoma. Int J Gynecol Cancer. 2015;25:135–44.CrossRefPubMed
70.
Sugarbaker PH, Yan TD, Stuart OA, Yoo D. Comprehensive management of diffuse malignant peritoneal mesothelioma. Eur J Surg Oncol. 2006;32(6):686–91.CrossRefPubMed
71.
•• Sugarbaker PH, Chang D. Long-term regional chemotherapy for patients with epithelial malignant peritoneal mesothelioma results in improved survival. Eur J Surg Oncol. 2017;43(7):1228–35. Strong data regarding long-term intraperitoneal chemotherapy for malignant peritoneal mesothelioma. CrossRefPubMed
72.
Sugarbaker PH. Pseudomyxoma peritonei and peritoneal metastases from appendiceal malignancy. (In) Sugarbaker PH (Ed). Cytoreductive Surgery & Perioperative Chemotherapy for Peritoneal Surface Malignancy. Textbook and Video Atlas (Second Edition). Cine-Med Publishers: Woodbury, CT, 2017, pp. 109–32.
73.
Gonzalez-Moreno S, Yan H, Alcorn KW, Sugarbaker PH. Malignant transformation of “benign” cystic mesothelioma of the peritoneum. J Surg Oncol. 2002;79(4):243–51.CrossRefPubMed
74.
Ihemelandu C, Sugarbaker PH. Clinicopathologic and prognostic features in patients with peritoneal metastasis from mucinous adenocarcinoma, adenocarcinoma with signet ring cells, and Adenocarcinoid of the appendix treated with cytoreductive surgery and perioperative intraperitoneal chemotherapy. Ann Surg Oncol. 2016;23(5):1474–80.CrossRefPubMed
75.
Elias D, Benizri E, Pocard M, Ducreux M, Boige V, Lasser P. Treatment of synchronous peritoneal carcinomatosis and liver metastases from colorectal cancer. Eur J Sur Oncol. 2006;32(6):632–6.CrossRef
76.
Yan TD, Morris DL, Kusamura S, Baratti D, Deraco M. Preoperative investigations in the management of peritoneal surface malignancy with cytoreductive surgery and perioperative intraperitoneal chemotherapy: expert consensus statement. J Surg Oncol. 2008;98:224–7.CrossRefPubMed
77.
Jacquet P, Jelinek JS, Steves MA, Sugarbaker PH. Evaluation of computer tomography in patients with peritoneal carcinomatosis. Cancer. 1993;72(5):1631–6.CrossRefPubMed
78.
Koh JL, Yan TD, Glenn D, Morris DL. Evaluation of preoperative computed tomography in estimating peritoneal cancer index in colorectal peritoneal carcinomatosis. Ann Surg Oncol. 2009;16:327–33.CrossRefPubMed
79.
•• Sugarbaker PH, Sardi A, Brown G, et al. Concerning CT features used to select patients for treatment of peritoneal metastases, a pictoral essay. Int J Hyperth. 2017;33(5):497–504. CT of use in peritoneal metastases for many intraabdominal cancers. CrossRef
80.
Jacquet P, Jelinek JS, Chang D, Koslowe P, Sugarbaker PH. Abdominal computed tomographic scan in the selection of patients with mucinous peritoneal carcinomatosis for cytoreductive surgery. J Am Coll Surg. 1995;181:530–8.PubMed
81.
Yan TD, Haveric N, Carmignani P, Chang D, Sugarbaker PH. Abdominal computed tomography scans in the selection of patients with malignant peritoneal mesothelioma for comprehensive treatment with cytoreductive surgery and perioperative intraperitoneal chemotherapy. Cancer. 2005;15:839–49.CrossRef
82.
Rivard JD, Temple WJ, McConnell YJ, et al. Preoperative computed tomography does not predict resectability in peritoneal carcinomatosis. Am J Surg. 2014;207:760–5.CrossRefPubMed
83.
Suidan RS, Ramirez PT, Sarasohn DM, Teitcher JB, Mironov S, Iyer RB, et al. A multicenter prospective trial evaluating the ability of preoperative computed tomography scan and serum CA-125 to predict suboptimal cytoreduction at primary debulking surgery for advanced ovarian, fallopian tube, and peritoneal cancer. Gynecol Oncol. 2014;134(3):455–61.CrossRefPubMedPubMedCentral
84.
Goere D, Souadka A, Faron M, et al. Extent of colorectal peritoneal carcinomatosis: attempt to define a threshold above which HIPEC does not offer survival benefit: a comparative study. Ann Surg Oncol. 2015;22:2958–64.CrossRefPubMed
85.
Chi DS, Eisenhauer EL, Zivanovic O, Sonoda Y, Abu-Rustum NR, Levine DA, et al. Improved progression-free and overall survival in advanced ovarian cancer as a result of a change in surgical paradigm. Gynecol Oncol. 2009;114:26–31.CrossRefPubMed
86.
Sugarbaker PH, Welch L, Mohamed F, Glehen O. A review of peritoneal mesothelioma at the Washington Cancer institute. Surg Oncol Clin N Am. 2003;12(3):605–21.CrossRefPubMed
87.
Glehen O, Mohamed F, Sugarbaker PH. Incomplete cytoreduction in 174 patients with peritoneal carcinomatosis from appendiceal malignancy. Ann Surg. 2004;240(2):275–85.CrossRef
88.
Look M, Chang D, Sugarbaker PH. Long-term results of cytoreductive surgery for advanced and recurrent epithelial ovarian cancers and papillary serous carcinoma of the peritoneum. Int J Gynecol Cancer. 2004;14(1):35–41.CrossRefPubMed
89.
Berthet B, Sugarbaker TA, Chang D, Sugarbaker PH. Quantitative methodologies for selection of patients with recurrent abdominopelvic sarcoma for treatment. Eur J Cancer. 1999;35(3):413–9.CrossRefPubMed
90.
Paul BK, Ihemelandu C, Sugarbaker PH. Prior surgical score: an analysis of the prognostic significance of an initial non-definitive surgical intervention in patients with peritoneal carcinomatosis of a colorectal origin undergoing cytoreductive surgery and hyperthermic intraperitoneal chemotherapy. Abstract in Diseases of Colon and Rectum, March 2016.
91.
Van der Speeten K, Stuart OA, Sugarbaker PH. Pharmacology of perioperative intraperitoneal and intravenous chemotherapy in patients with peritoneal surface malignancy. Surg Oncol Clin N Am. 2012;21(4):577–97.CrossRefPubMed
92.
• Mohamed F, Sugarbaker PH. Intraperitoneal taxanes. Surg Oncol Clin N Am. 2003;12(3):825–33. First large group of patients showing favorable results. CrossRefPubMed
93.
Bakrin N, Bereder JM, Decullier E, et al. Peritoneal carcinomatosis treated with cytoreductive surgery and Hyperthermic intraperitoneal chemotherapy (HIPEC) for advanced ovarian carcinoma: a French multicentre retrospective cohort study of 566 patients. Eur J Surg Oncol. 2013;22:1570–5.
94.
Sugarbaker PH, van der Speeten K. Surgical technology and pharmacology of hyperthermic perioperative chemotherapy. J Gastrointest Oncol. 2016;7(1):29–44.PubMedPubMedCentral
95.
96.
Elias D, Bonnay M, Puizillou JM, Antoun S, Demirdjian S, el Otmany A, et al. Heated intra-operative intraperitoneal oxaliplatin after complete resection of peritoneal carcinomatosis: pharmacokinetics and tissue distribution. Ann Oncol. 2002;13:267–72.CrossRefPubMed
97.
Van Ruth S, Verwaal VJ, Zoetmulder FAN. Pharmacokinetics of intraperitoneal mitomycin C. Surg Oncol Clin N Am. 2003;12:771–80.CrossRefPubMed
98.
Sugarbaker PH, Van der Speeten K, Stuart OA, et al. Impact of surgical and clinical factors on the pharmacology of intraperitoneal doxorubicin in 145 patients with peritoneal carcinomatosis. Eur J Surg Oncol. 2011;37:719–26.CrossRefPubMed
99.
Sticca RP, Dach BW. Rationale for hyperthermia with intraoperative intraperitoneal chemotherapy agents. Surg Oncol Clin N Am. 2003;12:689–701.CrossRefPubMed
100.
Sugarbaker PH. Laboratory and clinical basis for hyperthermia as a component of intracavitary chemotherapy. Int J Hyperth. 2007;23:431–42.CrossRef
101.
Jacquet P, Averbach A, Stuart OA, Chang D, Sugarbaker PH. Hyperthermic intraperitoneal doxorubicin: pharmacokinetics, metabolism, and tissue distribution in a rat model. Cancer Chemother Pharmacol. 1998;41:147–54.CrossRefPubMed
102.
Young JS, Lumsden CE, Stalker AL. The significance of the tissue pressure of normal testicular and of neoplastic (Brown-Pearce carcinoma) tissue in the rabbit. J Pathol Bacteriol. 1950;62:313–33.CrossRefPubMed
103.
Leunig M, Goetz AE, Dellian M, Zetterer G, Gamarra F, Jain RK, et al. Interstitial fluid pressure in solid tumors following hyperthermia: possible correlation with therapeutic response. Cancer Res. 1992;52:487–90.PubMed
104.
Urano M, Kuroda M, Nishimura Y. Invited review for the clinical application of thermochemotherapy given at mild temperatures. Int J Hyperth. 1999;15:79–107.CrossRef
105.
Sugarbaker PH, van der Speeten K. An Overview of Peritonectomy, Visceral Resection, and Therapeutic Laparoscopy for Peritoneal Surface Malignancy. (In) Sugarbaker PH (Ed). Cytoreductive Surgery & Perioperative Chemotherapy for Peritoneal Surface Malignancy. Textbook and Video Atlas (Second Edition). Cine-Med Publishers: Woodbury, CT, 2017, pp. 17–46.
106.
Benoit L, Cheynel N, Ortega-Deballon P, Giacomo GD, Chauffert B, Rat P. Closed hyperthermic intraperitoneal chemotherapy with open abdomen: a novel technique to reduce exposure of the surgical team to chemotherapy drugs. Ann Surg Oncol. 2008;15:542–6.CrossRefPubMed
107.
Yan TD, Black D, Savady R, Sugarbaker PH. A systematic review on the efficacy of cytoreductive surgery and perioperative intraperitoneal chemotherapy for pseudomyxoma peritonei. Ann Surg Oncol. 2007;14(2):484–92.CrossRefPubMed
108.
Feldman AL, Libutti SK, Pingpank JF, Bartlett DL, Beresnev TH, Mavroukakis SM, et al. Analysis of factors associated with outcome in patients with malignant peritoneal mesothelioma undergoing surgical debulking and intraperitoneal chemotherapy. J Clin Oncol. 2003;21(24):4560–7.CrossRefPubMed
109.
Hesdorffer ME, Chabot JA, Keohan ML, Fountain K, Talbot S, Gabay M, et al. Combined resection, intraperitoneal chemotherapy, and whole abdominal radiation for the treatment of malignant peritoneal mesothelioma. Am J Clin Oncol. 2008;31(1):49–54.CrossRefPubMed
110.
Deraco M, Nonaka D, Baratti D, Casali P, Rosai J, Younan R, et al. Prognostic analysis of clinicopathologic factors in 49 patients with diffuse malignant peritoneal mesothelioma treated with cytoreductive surgery and intraperitoneal hyperthermic perfusion. Ann Surg Oncol. 2006;13(2):229–37.CrossRefPubMed
111.
Verwaal VJ, van Ruth S, Witkamp A, Boot H, van Slooten G, Zoetmulder FAN. Long-term survival of peritoneal carcinomatosis of colorectal origin. Ann Surg Oncol. 2005;12(1):65–71.CrossRefPubMed
112.
Shen P, Hawksworth J, Lovato J, Loggie BW, Geisinger KR, Fleming RA, et al. Cytoreductive surgery and intraperitoneal hyperthermic chemotherapy with mitomycin C for peritoneal carcinomatosis from nonappendiceal colorectal carcinoma. Ann Surg Oncol. 2004;11(2):178–86.CrossRefPubMed
113.
Elias D, Gilly F, Boutitie F, Quenet F, Bereder JM, Mansvelt B, et al. Peritoneal colorectal carcinomatosis treated with surgery and perioperative intraperitoneal chemotherapy: Restrospective analysis of 523 patients from a multicentric French study. J Clin Oncol. 2010;28(1):63–8.CrossRefPubMed
114.
Verwaal VJ, van Ruth S, de Bree E, van Slooten GW, van Tinteren H, Boot H, et al. Randomized trial of cytoreduction and hyperthermic intraperitoneal chemotherapy versus systemic chemotherapy and palliative surgery in patients with peritoneal carcinomatosis of colorectal cancer. J Clin Oncol. 2003;21(20):3737–43.CrossRefPubMed
115.
Verwaal VJ, Bruin S, Boot H, van Slooten G, van Tinteren H. 8-year follow-up of randomized trial: Cytoreduction and hyperthermic intraperitoneal chemotherapy versus systemic chemotherapy in patients with peritoneal carcinomatosis of colorectal cancer. Ann Surg Oncol. 2008;15(9):2426–32.CrossRefPubMed
116.
Yan TD, Black D, Savady R, Sugarbaker PH. Systematic review on the efficacy of cytoreductive surgery combined with perioperative intraperitoneal chemotherapy for peritoneal carcinomatosis from colorectal carcinoma. J Clin Oncol. 2006;24(24):4011–9.CrossRefPubMed
117.
Xu DZ, Zhan YQ, Sun XW, Cao SM, Geng QR. Meta-analysis of intraperitoneal chemotherapy for gastric cancer. World J Gastroenterol. 2004;10:2727–30.CrossRefPubMedPubMedCentral
118.
Metadaten
Titel
Peritoneal Metastases from Gastrointestinal Cancer
verfasst von
Paul H. Sugarbaker
Publikationsdatum
01.08.2018
Verlag
Springer US
Erschienen in
Current Oncology Reports / Ausgabe 8/2018
Print ISSN: 1523-3790
Elektronische ISSN: 1534-6269
DOI
https://doi.org/10.1007/s11912-018-0703-0

Weitere Artikel der Ausgabe 8/2018

Current Oncology Reports 8/2018 Zur Ausgabe

Genitourinary Cancers (DP Petrylak and JW Kim, Section Editors)

Molecular Subtypes of Prostate Cancer

Breast Cancer (B Overmoyer, Section Editor)

Cardiac Toxicity from Breast Cancer Treatment: Can We Avoid This?

Integrative Care (C Lammersfeld, Section Editor)

Flaxseed Bioactive Compounds and Colorectal Cancer Prevention

Breast Cancer (B Overmoyer, Section Editor)

Where Do We Stand on the Integration of PARP Inhibitors for the Treatment of Breast Cancer?

Neuro-oncology (S Nagpal, Section Editor)

The Utility of Liquid Biopsy in Central Nervous System Malignancies

Integrative Care (C Lammersfeld, Section Editor)

Toxicity of Cancer Therapies in Older Patients

Neu im Fachgebiet Onkologie

Umsetzung der POMGAT-Leitlinie läuft

03.05.2024 DCK 2024 Kongressbericht

Seit November 2023 gibt es evidenzbasierte Empfehlungen zum perioperativen Management bei gastrointestinalen Tumoren (POMGAT) auf S3-Niveau. Vieles wird schon entsprechend der Empfehlungen durchgeführt. Wo es im Alltag noch hapert, zeigt eine Umfrage in einem Klinikverbund.

CUP-Syndrom: Künstliche Intelligenz kann Primärtumor finden

30.04.2024 Künstliche Intelligenz Nachrichten

Krebserkrankungen unbekannten Ursprungs (CUP) sind eine diagnostische Herausforderung. KI-Systeme können Pathologen dabei unterstützen, zytologische Bilder zu interpretieren, um den Primärtumor zu lokalisieren.

Sind Frauen die fähigeren Ärzte?

30.04.2024 Gendermedizin Nachrichten

Patienten, die von Ärztinnen behandelt werden, dürfen offenbar auf bessere Therapieergebnisse hoffen als Patienten von Ärzten. Besonders gilt das offenbar für weibliche Kranke, wie eine Studie zeigt.

Adjuvante Immuntherapie verlängert Leben bei RCC

25.04.2024 Nierenkarzinom Nachrichten

Nun gibt es auch Resultate zum Gesamtüberleben: Eine adjuvante Pembrolizumab-Therapie konnte in einer Phase-3-Studie das Leben von Menschen mit Nierenzellkarzinom deutlich verlängern. Die Sterberate war im Vergleich zu Placebo um 38% geringer.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen
Bildnachweise